The role of corticosteroids and stress in chronic pain conditions.
McEwen, Bruce S, Kalia, Madhu · Metabolism: clinical and experimental · 2010 · DOI
Quick Summary
This review explores how stress hormones (corticosteroids) and the body's stress response system affect chronic pain conditions, including ME/CFS. The authors explain that these hormones can have surprising and contradictory effects—sometimes reducing pain, sometimes increasing it—depending on the dose and where they act in the body. They examine how chronic stress and nervous system changes in conditions like ME/CFS, fibromyalgia, and IBS may be linked to pain through brain changes and immune system activity.
Why It Matters
This review directly addresses ME/CFS as a stress-related condition involving HPA axis dysfunction and chronic pain, proposing mechanistic links between neuroendocrine dysregulation and central sensitization. Understanding how stress hormones paradoxically affect pain may explain why standard pain treatments are ineffective in ME/CFS and could guide development of HPA-targeted interventions. The framework connecting allostatic load to pain generation is particularly relevant for post-exertional malaise and symptom exacerbation in ME/CFS.
Observed Findings
Corticosteroids produce paradoxical effects on pain—analgesia, hyperalgesia, or placebo analgesia—depending on dose and site of action (peripheral vs. central).
Glial cell activation in dorsal root ganglia prolongs neuronal hypersensitization through release of growth factors and immune-active substances.
Glutaminergic activity in the insula correlates positively with clinical pain perception.
ME/CFS, fibromyalgia, IBS, and burnout share features of high allostatic load and stress-related HPA axis dysregulation.
HPA axis components show dose-dependent and site-dependent paradoxical effects on different pain phenotypes.
Inferred Conclusions
HPA axis dysfunction and aberrant corticosteroid signaling play a central role in generating and maintaining chronic pain across multiple idiopathic conditions including ME/CFS.
Glial-immune interactions and central sensitization are key mechanisms by which stress and steroid dysregulation amplify pain signals.
Future pain therapeutics should target HPA axis restoration and glial-neuroimmune interactions rather than relying on conventional analgesics alone.
Remaining Questions
Do ME/CFS patients show specific patterns of HPA axis dysfunction (hypo- vs. hyperfunction) that predict pain severity or treatment response?
What This Study Does Not Prove
This review does not provide empirical evidence that corticosteroid dysfunction directly causes ME/CFS pain or establishes causality—it proposes mechanistic associations based on existing literature. The review does not demonstrate whether restoring HPA axis function would improve pain in ME/CFS patients, nor does it clarify which steroid dose ranges or timing would be therapeutic versus harmful. It does not establish that ME/CFS patients have demonstrable steroid abnormalities versus other chronic pain populations.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →